Navigation Links
Nymox Reports Completion of New 42 Month Follow-up Study of NX-1207,for BPH

HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Apr 18, 2007 - Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today completion of a new 42 month follow-up study of NX-1207 for benign prostatic hyperplasia (BPH). The study evaluated symptomatic progress of U.S. patients involved in the Company's two Phase 1-2 studies initiated in 2003. Individuals in the study were assessed for symptomatic improvement, treatment outcomes, and durability of efficacy. Patients in the study were assessed 3 1/2 years after NX-1207 treatment. The Company expects to conclude analysis of the data in the next 1-2 weeks and will be reporting the results once they are completed.

NX-1207 has successfully completed three U.S. trials to date. The company's most recently reported trial, a Phase 2 double-blind, placebo controlled, randomized study, showed positive efficacy and safety results for NX-1207 after 3 months in patients with BPH. Overall, patients treated with NX-1207 showed after 3 months a mean improvement of 9.35 points in AUA Symptom Score values, the standard scale used to evaluate BPH drugs and treatments. This improvement compares favorably to the 3.5 to 5 points reported in published studies of currently approved drugs for BPH and reached statistical significance when compared to placebo. Subjects treated with NX-1207 also showed an overall significant reduction in mean prostate volume. The results of the trial demonstrated the excellent safety and side effect profile of NX-1207. Subjects treated with NX-1207 had no serious side effects. In particular, patients given NX-1207 had no (0%) significant sexual side effects.

BPH afflicts approximately half of men over age 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems.

More information about Nymox is availab
'"/>




Page: 1 2

Related medicine technology :

1. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
2. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
3. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
4. Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
5. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
6. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
7. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
8. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
9. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Nymox Reports Completion New Month Follow Study for BPH
(Date:7/22/2014)... 22, 2014 Research and Markets ... Market by Equipment, by Reagent, by Application - Global ... http://photos.prnewswire.com/prnh/20130307/600769 Biopharmaceuticals ... is one of the most important and widely used ... application segment of the cell culture market in 2013. ...
(Date:7/22/2014)... BURLINGTON, Mass. , July 22, 2014 /PRNewswire/ ... of audited multiple sclerosis (MS) patients currently ... (DMT) Tecfidera have ever experienced flushing and/or ... few Tecfidera-treated patients are currently experiencing these ... or the effective medical management of such ...
(Date:7/22/2014)... Ill. , July 22, 2014 The ... staggering, killing 45 people each day. Twenty-three percent of ... National Survey on Drug Use and Health, making opioid ... employees are taking opioid painkillers at the correct dosage ... safety. Today, the National Safety Council ...
Breaking Medicine Technology:Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 2Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 3Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted 2Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted 35 things employers should know about prescription painkiller use 25 things employers should know about prescription painkiller use 3
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) ... difficile infection using National health insurance claims and ... 2, 2011 at the 21st Annual Scientific ... (SHEA).   (Logo:   http://photos.prnewswire.com/prnh/20090413/LA97352LOGO )Poster Presentation ...
... Pharmasset, Inc. (Nasdaq: VRUS ) today announced that ... for the Study of the Liver (EASL) on Saturday, April ... will review Pharmasset,s progress on the programs that are the ... To access a simultaneous webcast of this event via the ...
Cached Medicine Technology:Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality 2Pharmasset to Webcast an Investor Event From the EASL Meeting 2Pharmasset to Webcast an Investor Event From the EASL Meeting 3
(Date:7/22/2014)... Marietta, GA (PRWEB) July 23, 2014 Marietta, ... available than necessary homes. In an efforts to lower ... and Vicki Hammonds from the Tigg Neuter Project have joined ... to be sold. All proceeds will be presented to ... staff, and extended animal clinic family are excited to attend ...
(Date:7/22/2014)... DocbookMD , a HIPAA-secure mobile communication company, ... largest physician-centric mobile communication solutions in Texas at Memorial ... Created by Austin-based physicians, Tracey Haas, D.O., MPH, and ... into MHMD’s Accountable Care Network to enhance communication between ... put this capability at the fingertips of our physicians ...
(Date:7/22/2014)... Obtaining a bachelor’s degree in nursing just became ... medical experience. The School of Nursing at The University ... of an accelerated nursing degree program that provides course ... UNCG Veterans Access Program (VAP), will start January 2015 ... prior college credit, veterans who are RNs can earn ...
(Date:7/22/2014)... Air Conditioning & Heating Inc. is ... Daikin comfort pro dealer. This means that the company ... cooling system equipment. Only a select few businesses have ... being approved. , Daikin co-developed an R-410A refrigerant with ... Air Conditioning Market. They are also the inventor of ...
(Date:7/22/2014)... July 22, 2014 Dr. Jeremy K. ... surgical colleagues, have recently discussed the reasons for an ... in the periodontics profession are seeing the amount of ... exponentially. In fact, one surgeon reported that over 50% ... Although dental implants have a very high success rate ...
Breaking Medicine News(10 mins):Health News:Marietta Vet Clinic Hosts 2014 Dog Days of Summer Pet Rescue Event 2Health News:Memorial Hermann Physician Network Launches Physician Mobile Communication Solution Throughout Houston 2Health News:Memorial Hermann Physician Network Launches Physician Mobile Communication Solution Throughout Houston 3Health News:Memorial Hermann Physician Network Launches Physician Mobile Communication Solution Throughout Houston 4Health News:UNCG School of Nursing Fast-Tracks Medically Trained Veterans 2Health News:Air Conditioning & Heating Inc. Now an Authorized Daikin Comfort Pro Dealer 2Health News:Dr. Jeremy Ueno Can Help Treat Patients That Have Failing Implants 2Health News:Dr. Jeremy Ueno Can Help Treat Patients That Have Failing Implants 3
... Postoperative adhesions are a major complication in strabismus ... of preventing these adhesions by forming a biological barrier ... issue of the Journal of AAPOS , the ... and Strabismus, a team of researchers from Cairo University ...
... Researchers from Boston University School of Medicine (BUSM) and ... time in therapeutic range (TTR) should be used as ... thus improve patient outcomes. These findings appear in this ... . Oral anticoagulation with warfarin is received by ...
... Jan. 3 (HealthDay News) -- The pen may be mightier than ... Keeping a daily journal of snacks and meals is one ... Christopher J. Mosunic, a weight management and diabetes specialist at Greenwich ... exercise; it will always help you lose [weight] if you do ...
... is also available in Chinese on EurekAlert! ... sleep apnea often report that they feel like "a new ... A new study in the Jan. 1 issue of the ... anecdotal reports, showing that three weeks of CPAP therapy significantly ...
... -- Certain species of wildlife are adopting an urban ... increasing urbanization, people and animals are living closer together ... raccoons and opossums often scavenge leftovers from drive-thrus rather ... For this study, which appears in the December issue ...
... A new study of nursing home records shows ... and using it longer. The study also estimates that ... degree of dementia. Researchers hope the new data will ... seek to control Medicare costs. In newly published ...
Cached Medicine News:Health News:Use of amniotic membrane may cause complications in strabismus surgery 2Health News:Researchers measure quality of care in oral anticoagulation 2Health News:Study shows that CPAP therapy reduces fatigue, increases energy in patients with sleep apnea 2Health News:Study shows that CPAP therapy reduces fatigue, increases energy in patients with sleep apnea 3Health News:Hospice care increasing for nursing home patients with dementia 2Health News:Hospice care increasing for nursing home patients with dementia 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: